Follicular Lymphoma | Drug Pipeline update.
Rituxan success opens door to competition
Review of candidates in development for follicular lymphoma (FL) across the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK).
There are currently 22 drugs in clinical development for FL, seven of which are drugs in Phase III trials. Three Phase III drugs are monoclonal antibodies (MAbs) targeting the surface antigen CD20 and have the potential to directly compete with Rituxan in the management of FL. Rituxan resistance issues have boosted efforts to develop new generations of anti-CD20 MAbs, and to target new surface antigens in B cells for the management of FL. The development and clinical adoption of radio-immunotherapies has been limited in the FL market due to several logistical and economic issues associated with these drugs.
Datamonitor Healthcare has analyzed the FL pipeline, validating pipeline candidates against a variety of sources including BioMedTracker and company websites.
This is an Oncology analysis update from the Datamonitor Healthcare service, which provides regular and event-senstive research for key drugs and companies, treatment trends, patient populations and strategic issues.
- For more information on this research, please contact
- For current clients, please log-in to view the full analysis at: